Data demonstrate a scalable approach to better understand tumor cell behavior and inform drug development
DALLAS–(BUSINESS WIRE)–SingleCell Biotechnology, a biotechnology company developing technologies to measure tumor cell behavior at single-cell resolution, today announced the presentation of new data at the American Association for Cancer Research (AACR) Annual Meeting 2026 demonstrating an integrated, high-throughput assay capable of measuring clonal tumor cell growth across thousands of individual microenvironments while preserving the full distribution of proliferative behaviors.
The data show the platform can consistently measure differences in how individual tumor cells grow across multiple glioblastoma models. Importantly, it captures cell states that are often missed by traditional assays. It also enables tracking of single cells over time and recovery of specific cell populations for further analysis, allowing researchers to connect how cells behave with their underlying biology.
Tumor heterogeneity remains a major challenge in oncology drug development. Traditional preclinical approaches often rely on average responses across large groups of cells, which can miss the smaller populations that drive treatment resistance and disease progression. As a result, it remains difficult to identify and study the cells most responsible for relapse.
Presentation Details:
Poster Title: An Integrated High-throughput Assay for Proliferative Phenotypic and Omics
Presenter: Shiska Raut, Machine Learning Engineer
Poster ID: LB029
Session Date/Time: Sunday, April 19, 2026, 2:00 PM – 5:00 PM
Location: Poster Section 51, Board #9, San Diego Convention Center, San Diego, CA
About SingleCell Biotechnology
SingleCell Biotechnology is developing a high-throughput platform to measure tumor cell behavior at single-cell resolution. Its SCI-AP platform integrates microscale assays, automated imaging and machine-learning analysis to quantify tumor cell growth, migration and quiescent states within scalable laboratory workflows. By linking functional phenotypes to molecular signatures, the platform aims to provide deeper insight into tumor heterogeneity and support oncology drug discovery. Founded in 2022, the company is initially focusing on glioblastoma as a model of relapse-driven disease. In 2023, the company received a competitive product development grant from the Cancer Prevention and Research Institute of Texas (CPRIT) to further advance its platform.
Learn more at SingleCell Biotechnology.
Contacts
Media Contact:
Lauren Arnold
LA Communications
[email protected]
